Clinical Trial Disclosure Services: What They Do and Why Sponsors Use Them

“Clinical trial disclosure services” refers to a vendor and consultancy category, not a regulation or a registry. Sponsors use these services — sometimes standalone specialist firms, sometimes a service line inside a larger contract research organization (CRO) — to manage the operational work of getting a trial registered, its results posted, and its supporting documents made public across every jurisdiction and registry that applies to it. This guide covers what the service category actually does and why it exists; for the underlying legal obligations themselves, see CASRAI’s Clinical Trial Registration and Reporting Compliance guide, which this page assumes as background.

Disclosure services vs. the registries themselves

ClinicalTrials.gov, the EU’s Clinical Trials Information System (CTIS), ANZCTR, ISRCTN, CTRI, and the other primary registries in the WHO International Clinical Trials Registry Platform (ICTRP) network are the systems of record — the government- or nonprofit-operated databases a trial’s information legally has to live in. Disclosure services are the vendors sponsors hire to actually populate and maintain those records correctly, on time, and consistently across all of them. The distinction matters because a sponsor running a multi-country trial doesn’t have one registration obligation; it typically has several, running on different clocks, in different formats, sometimes in different languages, enforced by different authorities with different penalties.

Why the compliance burden created this market

A single multinational trial can trigger disclosure obligations that differ along at least three axes at once:

• Multiple registries with different rules. A US-regulated “applicable clinical trial” must register on ClinicalTrials.gov within 21 days of first enrollment and post summary results within 12 months of primary completion under the FDAAA 801 Final Rule (42 CFR Part 11). A trial conducted in the EU has, since 31 January 2025, had to route through CTIS — the sole mandatory EU registration/authorization system under the Clinical Trials Regulation (EU) No 536/2014 — as the older EudraCT system was retired. Other jurisdictions run their own primary registries (ANZCTR, ISRCTN, CTRI, ChiCTR, DRKS, JPRN, among others), each with its own data-entry conventions even though all conform to the WHO’s 24-item minimum data set.
• Multiple document types beyond the registry entry. Under the EU CTR, sponsors of adult trials must also post a lay (“plain language”) summary and a technical results summary to CTIS, generally within 12 months of the trial’s end — extended to 30 months for non-therapeutic Phase 1 trials and shortened to 6 months for pediatric trials. Separately, EMA’s Policy 0070 on publication of clinical data, relaunched in September 2023 for new active-substance marketing authorization applications, and Health Canada’s Public Release of Clinical Information (PRCI) guidance both require sponsors to make redacted, anonymized Clinical Study Reports (CSRs) publicly available — a different document, built to a different standard (personal-data and commercially-confidential-information redaction, not just plain-language rewriting), on a different timeline than either the registry entry or the lay summary.
• Language and locale requirements. The EU CTR’s lay summary requirement is not just “write it simply” — it generally has to be provided in the language(s) of the member state(s) where the trial was conducted, which means a trial run across several EU countries can require the same summary translated and locally reviewed multiple times, not once.

None of these obligations are optional add-ons: FDA can issue a public Notice of Noncompliance and pursue civil monetary penalties (up to $10,000 per day of continued violation, subject to inflation adjustment) for FDAAA 801 results-reporting failures, and funders including NIH can take independent funding actions. The operational question a sponsor actually faces isn’t “is this required” — it’s “who is going to track every deadline, in every format, across every one of these systems, without a single missed date or contradictory entry.” That coordination problem is what the vendor category exists to solve.

What clinical trial disclosure services actually do

Services offered under this category typically include some combination of:

• Global disclosure compliance calendars. Tracking every applicable deadline — registration windows, results-posting deadlines, lay-summary due dates, CSR redaction milestones — across every registry and jurisdiction a given trial or portfolio touches, and flagging conflicts or upcoming obligations before they’re missed.
• Registry data entry and quality control. Populating and maintaining trial records on ClinicalTrials.gov, CTIS, and other applicable registries, including reconciling protocol amendments back into already-posted records and checking that the same trial isn’t described inconsistently across two different registries.
• Plain-language summary (lay summary) writing. Converting technical trial results into the non-specialist-readable format regulators require, matched to whatever specific structure and length conventions the destination registry expects.
• Translation and localization. Producing the lay summary (and, where required, other disclosure documents) in the local language(s) required by each jurisdiction, with the linguistic and regulatory review needed to keep the translated version faithful to the source.
• CSR redaction and anonymization. Applying the personal-data and commercially-confidential-information redaction methodology that EMA Policy 0070 and Health Canada’s PRCI process require before a Clinical Study Report can be made public — a specialized, labor-intensive document review distinct from ordinary medical writing.
• Cross-registry consistency review. Checking that eligibility criteria, endpoints, and results are described the same way everywhere the trial is registered, since discrepancies between registries are a recurring source of scrutiny from journal editors, regulators, and transparency advocates alike.

Why sponsors outsource this instead of handling it in-house

A sponsor running one or two trials a year in one country can often manage disclosure obligations with existing regulatory-affairs staff. The case for a dedicated disclosure-services vendor strengthens as a sponsor’s trial portfolio spans more countries and more registries at once, because the work requires a combination of skills that rarely sits in one in-house role: regulatory knowledge of each registry’s specific requirements, medical writing capable of both technical accuracy and lay-audience clarity, translation/localization management, and enough process discipline to run a compliance calendar with no missed dates across dozens of simultaneous obligations. For research institutions and smaller or mid-size sponsors in particular, building that combined capability in-house is often less cost-effective than buying it as a service — the same buy-vs-build logic covered more generally in CASRAI’s Clinical Trial Outsourcing: In-House vs. Full-Service CRO vs. FSP guide. Some full-service CROs bundle disclosure work into their broader service offering; other sponsors engage standalone specialist firms that focus on disclosure and medical writing exclusively, sometimes alongside a CRO handling the rest of trial operations.

Evaluating a disclosure services vendor

Because this is a vendor category rather than a standardized credential or regulated role, evaluation criteria are largely about demonstrated operational capability rather than a single certification to check for:

• Registry breadth. Does the vendor have direct, current experience with every registry your trial portfolio actually touches — not just ClinicalTrials.gov, but CTIS and any other jurisdiction-specific registry relevant to your trial sites?
• Document-type coverage. Registry data entry, lay-summary writing, translation, and CSR redaction are genuinely different skill sets; confirm the vendor covers the specific combination you need rather than assuming one implies the others.
• Redaction methodology and audit trail. For CSR disclosure work specifically, ask how the vendor documents and justifies each redaction decision — regulators reviewing a submitted redacted CSR expect a defensible, consistent rationale, not ad hoc editing.
• Compliance-calendar transparency. Ask how deadlines are tracked and how far in advance you’ll be alerted to an upcoming obligation, since the cost of a missed FDAAA 801 or EU CTR deadline falls on the sponsor, not the vendor.
• Language and locale coverage. If your trial spans multiple EU member states, confirm the vendor’s translation process includes qualified regulatory/medical review in each target language, not machine translation alone.

Frequently asked questions

Is a clinical trial disclosure services vendor the same thing as a CRO?

Not necessarily. Some full-service CROs offer disclosure and medical-writing services as one part of a broader offering. Other vendors are standalone specialist firms focused specifically on registry disclosure, lay-summary writing, translation, and CSR redaction, and may be engaged alongside a CRO or independently of one.

Does using a disclosure services vendor transfer legal responsibility for compliance?

No. Under FDAAA 801 and the EU CTR, the “responsible party” or sponsor remains legally accountable for registration and results-reporting compliance regardless of who performs the underlying work. A vendor executes the disclosure tasks; it does not assume the sponsor’s regulatory liability.

What’s a plain-language (lay) summary, and why does it need its own vendor service?

It’s a non-technical summary of a trial’s results, written for a general public audience rather than clinicians or regulators. Under the EU Clinical Trials Regulation, sponsors must post one to CTIS — generally within 12 months of trial end — in the language(s) of the member state(s) where the trial ran, which is why lay-summary writing and translation are typically offered as a combined service rather than two separate ones.

What is CSR redaction, and how is it different from writing a lay summary?

Redaction is the process of removing personal data and commercially confidential information from a full Clinical Study Report before it’s made public under frameworks like EMA’s Policy 0070 or Health Canada’s PRCI process. It’s a document-review and anonymization task applied to the existing technical CSR, distinct from writing a new, simplified lay summary from scratch.

Related CASRAI resources

See also the Clinical Trial Registration and Reporting Compliance guide for the underlying legal requirements this service category exists to help sponsors meet; the Clinical Trial Outsourcing: In-House vs. Full-Service CRO vs. FSP guide for the broader buy-vs-build decision; the Clinical Trial Recruitment Companies guide for a comparable vendor-category writeup on the recruitment side of trial operations; and the Clinical Study Report (CSR) dictionary entry for the document format underlying CSR-redaction disclosure work. See also the Clinical Research pillar page for this guide’s broader cluster.